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Abstract: 48 
Background: HIV self-testing (HIVST) is recommended in Africa, but little is known 49 
about how this approach influences economic outcomes following subsequent 50 
antiretroviral treatment (ART) compared to facility-based HIV testing and counselling 51 
(HTC). 52 
 53 
Methods: HIV-positive participants attending HIV clinics, diagnosed by HIVST or 54 
facility-based HTC as part of a community cluster-randomised trial 55 
(ISRCTN02004005), were followed from initial assessment for ART until one-year 56 
postinitiation. Healthcare resource use was measured, and costing studies estimated 57 
total health provider costs. Participants were interviewed to establish direct non-58 
medical and indirect costs over the first-year of ART. Costs were adjusted to 2014 59 
US$ and INT$. Health-related quality of life was measured using EuroQol EQ-5D. 60 
Multivariable analyses estimated predictors of economic outcomes. 61 
 62 
Results: Of 325 participants attending HIV clinics for assessment for ART, 265 were 63 
identified through facility-based HTC, and 60 through HIVST; 168/265 (69.2%) and 64 
36/60 (60.0%), respectively, initiated ART. Mean total health provider assessment 65 
costs for ART initiation were US$22.79 (SE:0.56) and US$19.92 (SE:0.77) for 66 
facilitybased HTC and HIVST participants, respectively, and was US$2.87 67 
(bootstrap95%CI:US$1.01,US$4.73) lower for the HIVST group. Mean health 68 
provider costs for first-year of ART were US$168.65 (SE:2.02) and US$164.66 69 
(SE:4.21) for facility-based HTC and HIVST participants, respectively, and were 70 
comparable (bootstrap95%CI:-US$12.38,US$4.39). EQ-5D utility scores were 71 
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comparable between the two groups, and one-year after ART initiation had increased 72 
by 0.129 (SE:0.011) and 0.139 (SE:0.027) for facility-based HTC and HIVST 73 
participants, respectively. 74 
 75 
Conclusions: Once HIV self-testers are linked into HIV services, their economic 76 
outcomes are comparable to those linking to services after facility-based HTC. 77 
 78 
79 
Introduction 80 
There are now over 10 million Africans receiving anti-retroviral treatment (ART), the 81 
majority living in Eastern and Southern Africa.1 Despite this impressive achievement, 82 
over one half of HIV-positive individuals are still in need of treatment, and over one 83 
million people become infected every year.1 Meeting HIV elimination targets set by 84 
UNAIDS (“90-90-90”) will require novel approaches and significant investment in 85 
HIV testing and treatment services. HIV self-testing (HIVST), defined as an 86 
individual performing and interpreting their own HIV test,2 is one potential solution, 87 
and its scale-up in Africa is recommended.3  88 
 89 
HIVST offers an opportunity for early engagement of individuals in HIV services.4,5 90 
However, there is limited research around the cost implications and health-related 91 
quality of life (HRQoL) outcomes of HIV-positive individuals, identified through 92 
HIVST, after entering HIV care, to inform potential users and providers on the 93 
benefits of HIVST. The cost of providing HIVST is comparable to standard facility-94 
based HIV testing and counselling (HTC), but the lower yield of positive individuals, 95 
makes it more costly for identifying those who are HIV-positive.6 In contrast to 96 
HIVST, facility HTC services are more commonly accessed by those with advanced 97 
HIV disease,4,7 with individuals needing additional medical care to manage 98 
comorbidities.8,9 Engaging individuals early within HIV care and treatment through 99 
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HIVST may yield later cost savings. Improvements in HRQoL amongst those 100 
initiating ART after testing HIV-positive through facility HTC services have been 101 
demonstrated;10 this has yet to be shown for those identified through HIVST. 102 
Accurate and contemporaneous understanding of these economic outcomes will be 103 
essential to inform policy on scale-up.  104 
 105 
We recruited a cohort of adults attending HIV treatment clinics in Blantyre, Malawi, 106 
after they had undergone HIVST or facility-based HTC. Our primary aim was to 107 
compare the economic costs incurred by health providers and patients, and to compare 108 
health-related quality of life outcomes for adults diagnosed through HIVST or 109 
facility-based HTC.   110 
 111 
Methods 112 
Study design and participants 113 
We undertook a prospective cohort study in Blantyre, Malawi, between March 2013 114 
and January 2015. We recruited HIV-positive adults identified through either HIVST 115 
or facility-based HTC who were participants of a cluster-randomised trial 116 
investigating health outcomes of offering HIVST (ISRCTN02004005).4,5 Ethical 117 
approval was obtained from the College of Medicine Ethics Review Committee, 118 
University of Malawi, and the University of Warwick Biomedical Research Ethics 119 
Committee. All participants provided informed consent. 120 
 121 
The cluster-randomised trial comprised a population of approximately 34,000 122 
residents4-6 where adult HIV prevalence was approximately 18%.11 Participants in 123 
control clusters had access to routine facility-based HTC, and those in intervention 124 
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clusters were offered HIVST through resident community counsellors in addition to 125 
facility-based HTC. Participants who self-tested did not have to disclose their HIV 126 
test result to community counsellors but were offered post-test counselling, advice on 127 
where to seek care and a “self-referral card” for HIV clinics. HIVST was provided in 128 
the intervention clusters for a two-year period, starting in February 2012.  129 
 130 
We recruited participants from three HIV clinics located in the study areas: Queen 131 
Elizabeth Central Hospital (QECH), Ndirande Health Centre and Chilomoni Health 132 
Centre. At the start of this study, these clinics had initiated 19,929, 6,656 and 4,485 133 
individuals onto ART, respectively.12 Eligible participants were HIV-positive adults 134 
(aged>=18 years) attending for first assessment for ART initiation and resident within 135 
trial clusters (verified using global position system-based “Map Book”13). Participants 136 
who had not accessed either HIVST or facility-based HTC, or who had been assessed 137 
for ART initiation or started ART at another location, were excluded.  138 
 139 
All care was provided by the routine health system. HIV-positive individuals 140 
underwent CD4 count measurements, tuberculosis (TB) screening, provision of 141 
cotrimoxazole, and ART adherence counselling. Multiple visits may have been 142 
required to complete this assessment. Those who met Malawi national ART eligibility 143 
criteria (CD4 count <350 cells/mm3 or WHO stage 3 or 4, or breastfeeding or 144 
pregnant) were initiated onto ART. 145 
 146 
Participants initiated onto ART returned to the HIV clinic at regular intervals for 147 
assessment by clinic nurses (or clinical officers [available at all clinics], or doctors 148 
[available at QECH only] if unwell). At clinic visits, ART medication was provided, 149 
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adherence and response to treatment was assessed, and other clinical problems (e.g. 150 
TB) managed. Visits varied in frequency, depending on response to ART.  151 
 152 
We interviewed participants after each visit to the HIV clinic and if they were 153 
initiated onto ART, they were followed-up for one year. On recruitment, the study 154 
team administered structured questionnaires, recording age, sex, marital status, 155 
educational attainment, employment status, self-reported income, mode of HIV 156 
testing (HIVST, or facility HTC), WHO clinical stage, CD4 count prior to starting 157 
ART and tracing details. Participants were defined as lost to follow-up if they did not 158 
return for scheduled clinic visits and could not be traced.  159 
 160 
Direct health provider costs 161 
After each visit to the HIV clinic the study team used structured questionnaires to 162 
record healthcare resources for each participant, including medical personnel seen, 163 
investigations performed, and ART and other medications prescribed. Resources 164 
related to hospitalisation were not available from participants’ HIV clinic records. 165 
Primary resource-based costing was undertaken to estimate unit costs for each 166 
resource input, and consequently total direct health provider costs.14,15 Appendix A 167 
http://links.lww.com/QAI/A996provides a detailed description of the costing process, 168 
and Appendix B http://links.lww.com/QAI/A996 the estimated unit costs estimated 169 
for healthcare resources from the primary costing studies. 170 
 171 
Direct non-medical and indirect costs 172 
An interviewer-administered questionnaire was also used after each clinic visit to 173 
record participants’ direct non-medical and indirect costs and, where appropriate, 174 
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costs incurred by family member(s) or carer(s) who accompanied them to clinic. 175 
Development, language translations and pilot testing of questionnaires followed 176 
previous procedures.6 Direct non-medical costs included costs of transportation, food, 177 
drinks, and other items bought as a consequence of health center visits. For indirect 178 
costs, we recorded whether participants or their carers had taken time off work, and 179 
multiplied time by self-reported income.16 There are no formal payments to access 180 
public health services in Malawi.  181 
 182 
Health-related quality of life 183 
The Chichewa EuroQoL EQ-5D-3L17 was used to measure HRQoL after each clinic 184 
visit. Participants completed both the descriptive EQ-5D-3L system and the 185 
accompanying visual analogue scale (VAS).18 Responses to the five dimensions  186 
(mobility; self-care; usual activities; pain; anxiety) of the EQ-5D-3L descriptive 187 
system were converted into an EQ-5D utility score using a tariff. Tariff sets have been 188 
derived from national surveys of the general population, with a subset of the 243 189 
health states being valued, most commonly using the time trade-off method.18 As 190 
there is no Malawian EQ-5D tariff, we used the Zimbabwean EQ-5D tariff set to 191 
derive an EQ-5D utility score for each study participant at each time point.19 The 192 
VAS is similar to a thermometer, and ranges from 100 (best imaginable health state) 193 
to 0 (worst imaginable health state). Participants recorded how good or bad their 194 
health was on the day of the clinic visit by drawing a line on the scale. 195 
 196 
Statistical Analysis 197 
Analyses used Stata version 13.1 (Stata Corporation, Texas, USA).  Costs were 198 
converted into 2014 US Dollars and International Dollars.20,21 International dollars are 199 
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hypothetical units of currency that take into account differences in purchasing power 200 
across countries, thereby providing a means of comparing cost estimates across 201 
jurisdictions. Principal component analysis was used to generate wealth quintiles 202 
combining socioeconomic variables, which included nine household assets, and home 203 
environment variables.22  204 
 205 
We undertook multiple imputation using chained equations to impute missing values 206 
for cost and HRQoL estimates for participants lost to follow-up.23 Comparable to 207 
previous studies, our imputation models included mode of HIV testing received, 208 
baseline CD4 count, age, sex, and socio-economic variables.24,25 We used predictive 209 
mean matching to impute missing values for cost and HRQoL outcomes as they were 210 
non-normally distributed, and to ensure imputed costs were non-negative.26  211 
 212 
We estimated the total direct health provider cost, total direct non-medical and 213 
indirect cost, and total societal costs for each study participant. For direct health 214 
provider costs, we first estimated total cost for clinic consultations, total costs for 215 
investigations and total costs for treatments. These costs were summed to estimate 216 
total direct health provider costs. Health provider costs only included the costs of 217 
providing HIV and related medical care at the clinics. The total societal cost was 218 
estimated by summing all direct and indirect costs. .  219 
 220 
We estimated costs for two time periods. The first was for the ART assessment period. 221 
This included all costs from first attendance to the HIV clinic, and continued until the 222 
clinic had decided whether a participant was eligible for ART initiation. The second 223 
was for the first year on ART, and included all costs from the first visit to be initiated 224 
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onto ART until the participant had been on ART for one year. We estimated mean 225 
differences in these costs by mode of HIV testing using bootstrap methods with 500 226 
replications to estimate bias-corrected 95% confidence intervals (CI).27 We undertook 227 
multivariable analysis to investigate the independent effects of mode of HIV testing 228 
on costs. The multivariable model was adjusted for age, sex and other socio-229 
demographic variables, in addition to baseline CD4 count.8 We used generalized 230 
linear models (GLM), and ran model diagnostics to determine optimal choices for 231 
distributional family and link functions.28 232 
 233 
For HRQoL assessments, we estimated EQ-5D utility and VAS scores immediately 234 
prior to ART initiation, and for those who initiated ART, after one-year of treatment. 235 
We estimated mean differences, and 95% bootstrapped CIs, in HRQoL outcomes by 236 
mode of HIV testing received. In addition, we undertook multivariable analysis to 237 
investigate the independent effects of mode of HIV testing and baseline CD4 count on 238 
the EQ-5D utility scores. The multivariable models were additionally adjusted for age, 239 
sex and other socio-demographic variables. As EQ-5D utility scores are non-normally 240 
distributed, negatively skewed and truncated at 1.0, we evaluated four commonly 241 
used estimators for our multivariable analyses: ordinary least squares (OLS) 242 
regression, Tobit regression, Fractional logit regression, and censored least absolute 243 
deviations (CLAD) regression.29-31 We compared mean squared error (MSE) and 244 
mean absolute error (MAE) statistics between observed and estimated EQ-5D utility 245 
scores to determine the choice of estimator. We also undertook sensitivity analysis 246 
using the UK York A1 tariff32 to investigate the impact of using an alternative tariff to 247 
determine EQ-5D utility scores.  248 
 249 
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Results 250 
325 trial residents attended the HIV clinics for assessment for ART initiation over the 251 
study period: 265 after facility-based HTC and 60 after HIVST (Figure 1). Of the 265 252 
facility-based HTC participants, 20 (7.5%) did not complete ART assessment 253 
procedures, 77 (28.8%) completed ART assessment but did not meet Malawian 254 
eligibility criteria for initiating ART, and 168 (62.9%) completed ART assessment 255 
procedures and initiated ART. Of the 60 HIVST participants, 5 (8.3%) did not 256 
complete ART assessment procedures, 19 (31.7%) were not eligible to start ART and 257 
36 (60.0%) initiated ART. There was no significant difference in the characteristics of 258 
ART assessed participants across the two groups, except for WHO clinical stage, 259 
where there was a higher proportion of missing data for the HIVST group (Table 1).  260 
 261 
The mean total health provider costs during the assessment period for ART initiation 262 
were US$22.79 for facility HTC participants, and US$19.92 for HIVST participants 263 
(Table 2). During this period, the mean health provider costs for clinic consultations 264 
were US$3.33 (bootstrap 95%CI: US$2.17-US$4.50) lower for the HIVST group. 265 
The mean health provider costs for drug and other medical treatments received were 266 
US$0.74 (bootstrap 95%CI: US$0.33-US$1.16) lower for the HIVST group. The 267 
mean health provider costs for investigations performed were not significantly 268 
different between the two groups. The mean total health provider cost was US$2.87 269 
(bootstrap 95%CI: US$1.01-US$4.73) lower for the HIVST group. During the 270 
assessment period for ART initiation, the mean total direct non-medical and indirect 271 
costs were US$3.31 for facility HTC participants, and US$2.65 for HIVST 272 
participants. The mean total direct non-medical and indirect costs were not 273 
significantly different between the two groups. The mean total societal cost over this 274 
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period was US$3.54 (bootstrap 95%CI: US$0.37-US$6.71) lower for the HIVST 275 
group.  276 
 277 
The mean total health provider costs during the first year following ART initiation 278 
were US$168.65 for facility HTC participants, and US$164.66 for HIVST 279 
participants (Table 3). There were no significant differences in mean health provider 280 
costs for clinic consultations, mean health provider costs for treatments and 281 
investigations, or for mean total health provider costs between the two groups. The 282 
mean total direct non-medical and indirect costs during the first year following ART 283 
initiation were US$10.44 for facility HTC participants, and US$12.03 for HIVST 284 
participants. The mean total direct non-medical and indirect costs were not 285 
significantly different between the two groups. The mean total societal costs during 286 
the first year following ART initiation were US$178.46 for facility HTC participants, 287 
and US$177.55 for HIVST participants. The mean total societal costs were not 288 
significantly different between the two groups. 289 
  290 
In the multivariable analysis (Table 4), after adjusting for participants’ socio-291 
demographic characteristics and CD4 count on ART assessment, the mean total 292 
provider cost for ART assessment was US$3.18 (95%CI: US$1.77-US$4.59) lower 293 
for the HIVST group. The mean total societal cost for ART assessment was US$3.86 294 
(95%CI: US$1.64-US$6.08) lower for the HIVST group. There were no significant 295 
differences in mean total provider costs or mean total societal costs during the first 296 
year following ART initiation between facility HTC and HIVST participants. 297 
Appendix C http://links.lww.com/QAI/A996 provides the results from the cost 298 
analysis in 2014 INT dollars.   299 
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 300 
The HRQoL outcomes for those who were assessed for ART, immediately prior to 301 
initiation and at one-year post ART initiation, and the change in HRQoL scores 302 
between these time points, are summarised in Table 5. There were no significant 303 
difference in EQ-5D utility and VAS scores immediately prior to or one year post 304 
ART initiation between the two groups. Participants who were initiated onto ART 305 
experienced improvements in EQ-5D utility and VAS scores. For facility HTC 306 
participants who started ART, EQ-5D utility scores increased by 0.129 (SE: 0.011) 307 
and VAS scores increased by 9.8 (SE: 1.7). For HIVST participants who started ART, 308 
EQ-5D utility scores increased by 0.139 (SE: 0.027) and VAS scores increased by 309 
10.4 (SE: 4.6). There were no significant differences between the two groups with 310 
regards to the change in EQ-5D utility and VAS scores after ART initiation.  311 
 312 
In the multivariable analysis (Table 6), the model diagnostics showed that the OLS 313 
estimator performed as well or better than the other estimators (Appendix D 314 
http://links.lww.com/QAI/A996). In the fully adjusted OLS model, there was no 315 
significant difference in the mean EQ-5D utility score by mode of HIV testing. In the 316 
fully adjusted OLS model, the mean EQ-5D utility score was 0.043 (95%CI: 0.008-317 
0.079) lower in individuals whose CD4 count was 50-200 cells/ul compared to those 318 
whose CD4 count was >=350 cells/ul on assessment for ART. The mean EQ-5D 319 
utility score was 0.230 (95%CI: 0.163-0.296) lower in individuals whose CD4 count 320 
was below 50 cells/ul compared to those whose CD4 count was >=350 cells/ul on 321 
assessment for ART.  322 
 323 
 324 
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Discussion 325 
The main finding of this study was that the economic costs of providing HIV care and 326 
ART to HIV-positive individuals identified through HIVST were comparable to those 327 
identified through standard facility-based HTC services. Health-related quality of life 328 
was worse amongst those with lower CD4 counts, with improvements seen after ART 329 
initiation, irrespective of mode of HIV testing. These findings emphasise that once 330 
HIV self-testers are linked into HIV services, their economic outcomes are 331 
comparable to those linked to services after facility-based HTC.  332 
 333 
Health provider costs for assessing HIV-positive individuals for ART initiation were 334 
lower for HIV self-testers. This difference was due to lower health provider costs 335 
associated with clinic consultations and from provision of medical treatments. 336 
Additionally, fewer HIV self-testers were clinically assessed as WHO stage 3 or 4. In 337 
comparison to community-based HIV testing services, individuals accessing HIV 338 
testing at health facilities were often unwell for other reasons (e.g. TB), or have more 339 
advanced HIV clinical disease.33 These individuals may need medical care for 340 
management for these other problems, or for investigation to exclude HIV associated 341 
illnesses prior to initiating ART. Although the cost savings demonstrated are small at 342 
the individual-level, at the population-level, these could be significant with increasing 343 
availability of HIVST.  344 
 345 
We estimated the annual health provider cost of managing a patient on ART to be 346 
approximately 2014 US$170, comparable to previous estimates for Malawi (US$136 347 
per person per year in 2011).34 Health provider and societal costs were not affected by 348 
modality of HIV testing prior to entering HIV care services. Malawi has followed a 349 
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public health approach to scaling-up its HIV treatment services with less reliance on 350 
diagnostic tests for clinical assessment, and therefore the majority of individuals 351 
utilise comparable levels of healthcare resources.35 We did not find differences in 352 
healthcare utilisation between the two groups. Although it is reassuring that these 353 
costs were comparable, the findings highlight opportunities to explore how HIV 354 
treatment should be provided as we move towards universal access to ART.36  355 
 356 
The study demonstrates the relatively high costs incurred by patients when accessing 357 
HIV care. Individuals incurred a cost of approximately US$3 during their assessment 358 
for ART eligibility, and US$13 during the first year following ART initiation. The 359 
majority of Malawians live on less than $2 a day.37 Anti-retroviral therapy is provided 360 
free, but those accessing care incur costs of transport or because of taking time off 361 
work to attend clinics.38 These costs can also have a negative impact on adherence to 362 
therapy.39,40 ART can be effectively provided in people’s homes through community 363 
distribution models.5,41 Further work is needed to explore the risks and benefits of 364 
home provision of treatment.  365 
 366 
HRQoL as measured by the EQ-5D has been shown to be responsive to change 367 
amongst HIV-positive patients in high-income settings,42 but few studies have used 368 
this measure in sub-Saharan African settings.10 The EQ-5D utility score provides an 369 
objective assessment of HRQoL for cost-utility analysis, with the VAS scores 370 
reflecting respondents’ own assessments of their HRQoL. We found EQ-5D utility 371 
scores to be significantly associated with an HIV-positive individual’s CD4 count, 372 
with improvements after initiation of ART. Participants also reported higher VAS 373 
scores after ART initiation. The findings support the beneficial impact of ART on 374 
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both quality and quantity of life and illustrate the importance of reaching those not in 375 
care before their disease advances. The mode of HIV testing had no independent 376 
impact on HRQoL outcomes. 377 
 378 
This study is not without its limitations. The numbers recruited into the study were 379 
small, and many were lost to follow-up. Although we undertook multiple imputation 380 
to account for this, our findings may be limited because those lost to follow-up are 381 
potentially a sicker population, with poorer HRQoL, and, had they remained in care, 382 
higher healthcare resource use. We were not able to include healthcare resources 383 
utilized as a result of hospitalisation, as there was no routine medical record keeping 384 
or linking of records between community, outpatient and inpatient services. 385 
Furthermore, some of the unit costs estimated for the healthcare resource inputs, for 386 
example costs of consultations with a healthcare worker, represent average costs for 387 
average reported duration of consultations. These information system issues reduced 388 
our ability to detect differences in economic outcomes, but are unlikely to bias our 389 
findings.  390 
 391 
A further limitation is that the EQ-5D tool only evaluates HRQoL across five health 392 
dimensions and may therefore not capture all relevant aspects of HRQoL. The lack of 393 
a Malawian tariff led us to use the Zimbabwean tariff to derive EQ-5D-3L utility 394 
scores. However, the EQ-5D tool is widely used for health economic analyses, and it 395 
is accepted practice to use tariffs from another country where none exists for the 396 
country of interest provided the two populations would value health comparably.15 A 397 
final study limitation is that the recent change in ART initiation guidelines36 means 398 
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that we are unable to comment on the economic outcomes of those who would in the 399 
future start treatment with early HIV disease. 400 
 401 
In conclusion, we found that once HIV self-testers link into HIV treatment services, 402 
the costs of providing HIV care and improvements in HRQoL from ART are no 403 
different to those identified through facility-based HTC. The findings add to the 404 
growing literature supporting the scale-up of HIVST in the region. Full economic 405 
evaluations are needed to explore whether implementing HIVST is cost-effective. Our 406 
assessments of economic costs and preference-based HRQoL outcomes can help 407 
inform such analyses. 408 
 409 
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Figure 1: Participant recruitment and follow-up 549 
*Malawi national ART eligibility criteria during study period: CD4 count <350 cells/mm3; WHO stage 550 
3 or 4; breastfeeding; or pregnant 551 
**Loss to follow-up from this health economic study 552 
 553 
AC
CE
PT
ED
Copyright  2017 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
 1 
Table 1: Characteristics of ART assessed participants   1 
Facility HTC 
participants 
HIVST 
participants 
 
n (%) n (%) 
 
 
p-value* 
All  265 60  
Male 110 (41.5%) 20 (33.3%) 0.243 
Sex 
Female 155 (58.5%) 40 (66.7%)  
18-24 32 (12.1%) 11 (18.3%) 0.430 
25-39 169 (63.8%) 36 (60.0%)  Age (years) 
40+ 64 (24.2%) 13 (21.7%)  
Single (never-married) 19 (7.2%) 4 (6.7%) 0.884 
Married/Cohabiting 183 (69.1%) 39 (65.0%)  
Separated/Divorced 42 (15.85%) 12 (20.0%)  
Marital status 
Widower/Widow 21 (7.9%) 5 (8.3%)  
Up to standard 8 166 (62.6%) 44 (73.3%) 0.122 
Up to form 6 98 (37.0%) 15 (25.0%)  
Educational 
attainment 
University or training college 1 (0.4%) 1 (1.7%)  
0 Kwacha/week 89 (33.6%) 20 (33.3%) 0.296 
Up to 4,000 Kwacha/week 75 (28.3%) 16 (26.7%)  
4,000 to 8,000 kwacha/week 42 (15.85%) 10 (16.7%)  
8,000 to 12,000 kwacha/week 27 (10.2%) 2 (3.3%)  
Income 
Over 12,000 kwacha/week 32 (12.1%) 12 (20.0%)  
Formal employment 74 (27.9%) 9 (15.0%) 0.358 
Informal employment/Unemployed 106 (40.5%) 29 (48.3%)  
School/University 7 (2.6%) 2 (3.3%)  
Retired 2 (0.8%) 0 (0.0%)  
Housework 74 (27.9%) 20 (33.3%)  
Employment 
status 
Sick leave 2 (0.75%) 0 (0.0%)  
Highest quintile 55 (20.75%) 10 (16.7%) 0.106 
2nd highest quintile 53 (20.0%) 17 (28.3%)  
Middle quintile 57 (21.5%) 9 (15.0%)  
2nd lowest quintile 53 (20.0%) 7 (11.7%)  
Socio-
economic 
position
¶
 
Lowest quintile 47 (17.7%) 17 (28.3%)  
CD4 count>=350 89 (33.6%) 23 (38.3%) 0.943 
CD4 count 200-350 68 (25.7%) 14 (23.3%)  
CD4 count 50-200 76 (26.7%) 17 (28.3%)  
CD4 count <50 13 (4.9%) 3 (5.0%)  
 
 
CD4 Count 
Not done or missing 19 (7.2%) 3 (5.0%)  
Stage 1 64 (24.2%) 16 (26.7%) 0.031 
Stage 2 48 (18.1%) 10 (16.7%)  
Stage 3 45 (17.0%) 3 (5.0%)  
Stage 4 6 (2.3%) 0 (0%)  
WHO clinical 
stage 
Not done or missing 102 (38.5%) 31 (51.7%)  
¶
Socio-economic position estimated though undertaking principal component analysis of responses to assets and housing 2 
environment 3 
*Chi squared 4 
 5 
 6 
 7 
 8 
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 2 
Table 2: ART assessment costs by mode of HIV testing (2014 US Dollars)  9 
     Mean differences 
(95% CI)* 
   N Mean (SE) HIVST v 
Facility HTC 
Facility HTC 265 8.65 (0.32) Clinic 
consultations
1 
HIVST 60 5.32 (0.49) 
-3.33 
(-4.50, -2.17) 
Facility HTC 265 15.05 (0.41) 
Investigations
2 
HIVST 60 14.80 (0.45) 
-0.25 
(-1.37, 0.87) 
Facility HTC 265 1.71 (0.12) 
Treatments
3 
HIVST 60 0.96 (0.17) 
-0.74 
(-1.16, -0.33) 
Facility HTC 265 22.79 (0.56) 
Direct health 
provider cost 
(2014 US$) 
Total 
HIVST 60 19.92 (0.77) 
-2.87 
(-4.73, -1.01) 
Facility HTC 265 3.31 (0.41) Total direct non-medical and 
indirect cost (2014 US$) HIVST 60 2.65 (0.93) 
-0.67 
(-2.65, 1.31) 
Facility HTC 265 26.10 (0.75) 
Total societal cost (2014 US$) 
HIVST 60 22.57 (1.44) 
-3.54 
(-6.71, -0.37) 
ART: Anti-retroviral treatment 10 
*Bootstrapped 95%CI 11 
1: includes cost of clinic visit and consultation with health professional  12 
2: includes cost of CD4 count and TB diagnostics  13 
3: includes cost for cotrimoxazole, condoms and other medications  14 
 15 
Table 3: First year ART costs by mode of HIV testing (2014 US Dollars)  16 
     
Mean differences 
(95% CI)* 
   N Mean (SE) 
HIVST v 
Facility HTC 
Facility HTC 165 23.91 (1.04) Clinic 
consultations
1 
HIVST 36 19.88 (2.28) 
-4.04 
(-8.68, 0.60) 
Facility HTC 165 144.74 (1.29) Investigations
2
 
+ Treatments
3 
HIVST 36 144.78 (2.74) 
-0.04 
(-5.71, 5.79) 
Facility HTC 165 168.65 (2.02) 
Direct health 
provider cost 
(2014 US$) 
Total 
HIVST 36 164.66 (4.21) 
-4.00 
(-12.38, 4.39) 
Facility HTC 165 13.26 (2.13) Total direct non-medical and 
indirect cost (2014 US$) HIVST 36 14.72 (4.81) 
1.46 
(-7.99, 10.91) 
Facility HTC 165 181.91 (3.34) 
Total societal cost (2014 US$) 
HIVST 36 179.38 (7.70) 
-2.54 
(-17.74, 12.67) 
ART: Anti-retroviral treatment 17 
*Bootstrapped 95%CI 18 
1: includes cost of clinic visit and consultation with health professional  19 
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 3 
2: costs of investigations combined with costs for treatments, as Malawi HIV guidelines at time of study were for clinical 20 
monitoring and hence few participants had investigations performed during study period.  21 
3: includes cost for anti-retroviral drugs, cotrimoxazole, condoms and other medications 22 
 23 
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 4 
Table 4: Multivariable analysis exploring relationship between CD4 count and mode of HIV testing, and ART assessment and first year ART 24 
costs (2014 US Dollars)*    25 
 
Total health provider cost (2014 US Dollars) 
 
Total societal cost (2014 US Dollars) 
ART assessment  
(n=325) 
Frist year on ART 
(n=201) 
ART assessment  
(n=325) 
Frist year on ART 
(n=201) 
 
 
 
 
Coef (95% CI) Coef (95% CI)** Coef (95% CI) Coef (95% CI)** 
Facility HTC Ref Ref Ref Ref Mode of HIV 
testing  HIVST -3.18 (-4.59, -1.77) -5.28 (-11.67, 1.11) -3.86 (-6.08, -1.64) -4.72 (-14.89, 5.45) 
CD4 count >350 cells/μl Ref Ref Ref Ref 
CD4 count 200-350 cells/μl 1.19 (-1.43, 3.82) -2.15 (-9.74, 5.45) 2.58 (-1.11, 6.27) -3.56 (-7.71, 14.84) 
CD4 count 50-200 cells/μl 0.57 (-1.00, 2.14) -4.60 (-12.56, 3.35) 1.64 (-0.81, 4.09) 0.98 (-7.78, 9.74) 
CD4 count <50 cells/μl -0.45 (-3.31, 2.40) -3.47 (-17.57, 10.62) 1.00 (-3.60, 5.60) -6.68 (-25.74, 12.38) 
 
 
 
Baseline CD4 
count Not done or missing -16.01 (-17.76, -14.25) -4.91 (-18.15, 8.34) -16.41 (-18.81, -14.01) -3.53 (-24.23, 17.17) 
Constant 23.00 (19.46, 26.52) 178.19 (163.99, 192.38) 22.82 (18.32, 27.32) 189.18 (175.49, 202.88) 
Model adjusted for modality of HTC, CD4 count, age, sex, martial status, educational attainment, income and wealth quintile 26 
Total cost = constant + β(Modality of HIV testing) + β(Baseline CD4 count) + β(age) + β(sex) + β(marital status) + β(educational attainment) + β(income) + β(wealth quintile) + ε 27 
*Findings from Generalized Linear Model with Poisson distribution and Identity link function. Distributional family (Poisson) describes the distribution of the data, whilst the link function describes the relationship 28 
between the linear predictor and the mean of the response (cost). 29 
**Findings from ten imputed datasets with coefficients calculated using Rubin’s rules23  30 
 31 
 32 
 33 
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 34 
 35 
Table 5: Health-related quality of life outcomes immediately prior to and one-year after ART initiation by mode of HIV testing  36 
     
Mean differences 
(95% CI)* 
   N Mean (SE) HIVST v Facility HTC 
Facility HTC ART assessment – all 264 0.836 (0.008) 
HIVST ART assessment – all 60 0.854 (0.018) 
0.018 (-0.020, 0.056) 
Facility HTC ART assessment – initiated ART 164 0.837 (0.010) 
HIVST ART assessment – initiated ART 36 0.836 (0.025) 
-0.001 (-0.055, 0.054) 
Facility HTC One year post-ART** 165 0.965 (0.006) 
EQ-5D utility 
score 
HIVST One year post-ART** 36 0.975 (0.011) 
0.010 (-0.017, 0.037) 
 Facility HTC Change on ART**  165 0.129 (0.011) 
 HIVST Change on ART**  36 0.139 (0.027) 
0.011 (-0.047, 0.068) 
Facility HTC ART assessment 264 73.0 (1.0) 
HIVST ART assessment 60 73.5 (2.4) 
0.5 (-4.7, 5.7) 
Facility HTC ART assessment – initiated ART 164 70.9 (1.3) 
HIVST ART assessment – initiated ART 36 74.1 (3.4) 
3.2 (-4.2, 10.6) 
Facility HTC One year post-ART** 165 80.8 (1.4) 
VAS score 
HIVST One year post-ART** 36 84.5 (3.6) 
3.7 (-3.8, 11.3) 
 Facility HTC Change on ART**  165 9.8 (1.7) 0.6 (-8.9, 10.0) 
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 HIVST Change on ART**  36 10.4 (4.6) 
Facility HTC ART assessment 264 0.793 (0.012) 
HIVST ART assessment 60 0.813 (0.028) 
0.020 (-0.037, 0.077) 
Facility HTC ART assessment – initiated ART 164 0.793 (0.015) 
HIVST ART assessment – initiated ART 36 0.785 (0.039) 
-0.009 (-0.093, 0.076) 
Facility HTC One year post-ART** 165 0.961 (0.007) 
EQ-5D utility 
score 
(UK tariff) 
HIVST One year post-ART** 36 0.973 (0.013) 
0.013 (-0.018, 0.044) 
 Facility HTC Change on ART**  165 0.167 (0.016) 
 HIVST Change on ART**  36 0.189 (0.040) 
0.022 (-0.062, 0.105) 
ART: Anti-retroviral treatment 37 
*Bootstrapped 95%CI 38 
**Findings from ten imputed datasets with overall differences in mean costs calculated using Rubin’s rules23 39 
  40 
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 7 
Table 6: Multivariable analysis exploring relationship between CD4 count, mode of 41 
HIV testing and pre-ART EQ-5D utility score*    42 
EQ-5D utility score 
(Zimbabwean Tariff) 
EQ-5D Utility Score  
(UK Tariff)** 
 
 
 
 
Coef (95% CI) Coef (95% CI) 
Facility HTC Ref Ref 
Modality of HIV 
testing HIVST 
0.022 
(-0.015, 0.058) 
0.026 
(-0.028, 0.080) 
CD4 count>=350 Ref Ref 
CD4 count 200-350 
-0.011 
(-0.048, 0.026) 
-0.021 
(-0.075, 0.033) 
CD4 count 50-200 
-0.043 
(-0.079, -0.008) 
-0.057 
(-0.110, -0.004) 
CD4 count <50 
-0.230 
(-0.296, -0.163) 
-0.371 
(-0.469, -0.272) 
 
 
 
Baseline CD4 count 
Not done or missing 
-0.019 
(-0.079, 0.040) 
-0.035 
(-0.122, 0.053) 
Constant 
0.878 
(0.801, 0.956) 
0.834 
(0.719, 0.948) 
Model adjusted for modality of HTC, CD4 count, age, sex, martial status, educational attainment, income and wealth quintile 43 
*Findings from OLS estimator 44 
Utility score = constant + β(Modality of HIV testing) + β(Baseline CD4 count) + β(age) + β(sex) + β(marital status) + 45 
β(educational attainment) + β(income) + β(wealth quintile) + ε 46 
**Findings from sensitivity analysis 47 
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